SCHEMBL6763197

SCHEMBL6763197

Cc1c(Cl)ccc(S(=O)(=O)CNCC(=O)NCC(=O)O)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.40
CA1 P00915 10/20 0.39
CA2 P00918 10/20 0.39
BDKRB1 P46663 4/20 0.38
BDKRB2 P30411 1/20 0.38
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.34
ITGB1 P05556 1/20 0.33
ITGA5 P08648 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
ATM Q13315 1/20 0.33
USP5 P45974 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6884908 0.82 POLB (0.44) CA1CA2POLB
SCHEMBL6762354 0.80 WDR5 (0.37) WDR5CA1CA2BDKRB1BDKRB2
SCHEMBL6762826 0.80 SHMT1 (0.44) CA1CA2BDKRB1USP5
SCHEMBL6764149 0.79 ALDH1A1 (0.43) CA1CA2POLBUSP5
SCHEMBL5118925 0.79 FABP4 (0.43) WDR5CA1CA2LMNAATM
SCHEMBL5113650 0.78 FABP4 (0.47) WDR5CA1CA2
SCHEMBL6763199 0.77 BDKRB1 (0.57) WDR5CA1CA2BDKRB1POLB
SCHEMBL3992993 0.76 WDR5 (0.40) WDR5BDKRB1BDKRB2LMNAPOLB
SCHEMBL4464905 0.76 WDR5 (0.39) WDR5BDKRB1BDKRB2LMNAPOLB
SCHEMBL5118265 0.75 WDR5 (0.40) WDR5BDKRB1BDKRB2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB WDR5 4094/4885CA1 2892/4885CA2 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.